Develops and manufactures ophthalmic devices for diagnosing and treating eye diseases. Provides systems and consumables for cataract, retinal, and refractive surgeries. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The gap is $122.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 18.8× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.63 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
Against everything we grade, CZMWY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: CZMWY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.